Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Advances in Melanoma
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Advances in Melanoma

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: closed (31 August 2024) | Viewed by 6681

Special Issue Editors

Dr. Amanda Kirane

E-Mail Website
Guest Editor
Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA
Interests: melanoma; non-melanoma; general surgery; skin cancer surgery; immunotherapy; intratumoral therapy
Dr. Sarah Bateni

E-Mail Website
Guest Editor
Department of Surgery, Division of Surgical Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Interests: skin and soft tissue malignancies; melanoma; nonmelanoma skin cancers; retroperitoneal and extremity sarcoma; neuroendocrine tumors

Special Issue Information

Dear Colleagues,

There has been rapid developments in melanoma science and modern immunotherapeutics in an effort to achieve the gold standard of precise, patient-tailored therapy to improve clinical outcomes and minimize toxicities associated with systemic checkpoint blockades. This Special Issue aims to provide an update for practicing clinicians with a comprehensive collection of articles and reviews.

To this end, we would like to invite original research in this area as well as state-of-the-art reviews, including reviews of emerging technologies and therapeutics, to be considered for inclusion in this issue. Examples include novel assays in development for biomarker assessment, evolving changes in relation to therapeutic timing and strategy, the best surgical practices (including post-immunotherapy patient selection, timing, and considerations for the de-escalation of surgery), the role of regional therapies in melanoma, special considerations in unique populations (such as patients with organ transplant or pregnancy status), current trends and guidelines for post-checkpoint failure treatment, the rapidly evolving application of cell therapies, and future directions in the field (including new preclinical modeling techniques and novel targets in immunotherapeutic resistance).

This Special Issue aims to present the most recent advances in the field of precision immunotherapy and their implications in the future care of melanoma patients. We look forward to your submission!

Dr. Amanda Kirane
Dr. Sarah Bateni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • skin cancer surgery
  • immunotherapy
  • intratumoral therapy
  • dermatology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 710 KiB  
Article
Scalp Melanoma: A High-Risk Subset of Cutaneous Head and Neck Melanomas with Distinctive Clinicopathological Features
by Rodolfo David Palacios-Diaz, Blanca de Unamuno-Bustos, Mónica Pozuelo-Ruiz, Enrico Giorgio Morales-Tedone, Rosa Ballester-Sánchez and Rafael Botella-Estrada
J. Clin. Med. 2023, 12(24), 7643; https://doi.org/10.3390/jcm12247643 - 13 Dec 2023
Viewed by 1713
Abstract
Scalp melanomas (SM) have been previously associated with poor overall and melanoma-specific survival rates. The aim of this study was to describe and compare the clinicopathological characteristics and survival outcomes of SM and non-scalp cutaneous head and neck melanoma (CHNM). An observational multi-center [...] Read more.
Scalp melanomas (SM) have been previously associated with poor overall and melanoma-specific survival rates. The aim of this study was to describe and compare the clinicopathological characteristics and survival outcomes of SM and non-scalp cutaneous head and neck melanoma (CHNM). An observational multi-center retrospective study was designed based on patients with CHNM followed in two tertiary care hospitals. A hundred and fifty-two patients had CHNM, of which 35 (23%) had SM. In comparison with non-scalp CHNM, SM were more frequently superficial spreading and nodular subtypes, had a thicker Breslow index median (2.1 mm vs. 0.85 mm), and a higher tumor mitotic rate (3 vs. 1 mitosis/mm2) (p < 0.05). SM had a higher risk of recurrence and a higher risk of melanoma-specific death (p < 0.05). In the multivariate analysis, scalp location was the only prognostic factor for recurrence, and tumor mitotic rate was the only prognostic factor for melanoma-specific survival. We encourage routinely examining the scalp in all patients, especially those with chronic sun damage. Full article
(This article belongs to the Special Issue Clinical Advances in Melanoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 6666 KiB  
Review
Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review
by Abdulaziz Shebrain, Omer A. Idris, Ali Jawad, Tiantian Zhang and Yan Xing
J. Clin. Med. 2024, 13(18), 5409; https://doi.org/10.3390/jcm13185409 - 12 Sep 2024
Cited by 2 | Viewed by 2432
Abstract
Over the past several decades, advancements in the treatment of BRAF-mutant melanoma have led to the development of BRAF inhibitors, BRAF/MEK inhibitor combinations, anti-PD-1 therapy, and anti-CTLA4 therapy. Although these therapies have shown substantial efficacy in clinical trials, their sustained effectiveness [...] Read more.
Over the past several decades, advancements in the treatment of BRAF-mutant melanoma have led to the development of BRAF inhibitors, BRAF/MEK inhibitor combinations, anti-PD-1 therapy, and anti-CTLA4 therapy. Although these therapies have shown substantial efficacy in clinical trials, their sustained effectiveness is often challenged by the tumor microenvironment, which is a highly heterogeneous and complex milieu of immunosuppressive cells that affect tumor progression. The era of personalized medicine holds substantial promise for the tailoring of treatments to individual genetic profiles. However, tumor heterogeneity and immune evasion mechanisms contribute to the resistance to immunotherapy. Despite these challenges, tumor-infiltrating lymphocyte (TIL) therapy, as exemplified by lifileucel, has demonstrated notable efficacy against BRAF V600-mutant melanoma. Additionally, early response biomarkers, such as COX-2 and MMP2, along with FDG-PET imaging, offer the potential to improve personalized immunotherapy by predicting patient responses and determining the optimal treatment duration. Future efforts should focus on reducing the T-cell harvesting periods and costs associated with TIL therapy to enhance efficiency and accessibility. Full article
(This article belongs to the Special Issue Clinical Advances in Melanoma)
►▼ Show Figures

Figure 1

15 pages, 967 KiB  
Review
Review of Role of Surgery with Electroporation in Melanoma: Chemotherapy, Immunotherapy, and Gene Delivery
by M. Usman Ahmad, Allyson Walsh and Amanda Kirane
J. Clin. Med. 2024, 13(13), 3828; https://doi.org/10.3390/jcm13133828 - 29 Jun 2024
Cited by 1 | Viewed by 1861
Abstract
Electroporation with chemotherapy (ECT) is currently offered as a treatment in Europe for locoregional or metastatic melanoma with cutaneous lesions. However, the role of surgery and other forms of electroporation in melanoma requires further evaluation. Two reviewers used two databases to conduct a [...] Read more.
Electroporation with chemotherapy (ECT) is currently offered as a treatment in Europe for locoregional or metastatic melanoma with cutaneous lesions. However, the role of surgery and other forms of electroporation in melanoma requires further evaluation. Two reviewers used two databases to conduct a literature search and review, and 51 publications related to electroporation with chemotherapy, immunotherapy, or gene delivery were found. ECT appears to be effective in reducing tumor burden for surgical resection, replacing surgical intervention with evidence of complete regression in some lesions, and inducing both local and systemic immune effects. These immune effects are pronounced when ECT is combined with immunotherapy, with a statistically significant improvement in overall survival (OS). Other forms of electroporation, such as those using calcium chloride, an IL-12 plasmid, and vaccination, require further study. However, IL-12 plasmid electroporation may be inferior to ECT based on the evidence available. Furthermore, irradiation of the tumor prior to ECT treatment is negatively correlated with local response. Access to ECT is restricted in the US and requires further evaluation. More randomized controlled trials of ECT and electroporation treatment in locoregional melanoma are recommended. Full article
(This article belongs to the Special Issue Clinical Advances in Melanoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop